# US 2026/0016485 A1 · Endoglycosidase-assisted peptide mapping

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0016485 A1
- Document ID: US20260016485A1
- Status: Published application
- Kind: A1
- Application number: 19/266,789
- Filed: 2025-07-11
- Published: 2026-01-15
- Earliest claimed: 2024-07-11
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Haibo Qiu; Jieqiang Zhong; Ming Huang; Ning Li
- Web page: https://patentgrep.com/patent/US20260016485A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Endoglycosidase-assisted peptide mapping workflow systems for mass spectrometry (MS) characterization of non-consensus N-glycosylation in monoclonal antibodies (mAbs) are disclosed. The feasibility of the workflow was demonstrated by an atypical glycosite located within an NPNNXN (SEQ ID NO: 1) sequence in a 25-residue tryptic peptide. With the aids of endoglycosidase treatment, the resulting truncated glycan structures improved peptide ionization efficiency in MS and hence facilitated reliable quantitation of glycosite occupancy. The remaining mono-/di-saccharides served as a large mass tag allowing differentiation between the glycopeptide and deamidated peptide, thus allowing for database searching for glycosite localization and automation of the data processing workflow. This workflow offers an efficient solution for characterizing non-consensus N-glycosylation for the development of therapeutic mAbs.

## Claims

### Claim 1

A system for endoglycosidase-assisted peptide mapping workflow for a protein comprising non-consensus N-glycosylation, wherein the system comprises the steps of:
(a) providing a glycoprotein containing one or more non-consensus N-glycosites;
(b) digesting the glycoprotein using trypsin;
(c) de-glycosylating the digested glycoprotein by treatment with endoglycosidase;
(d) deactivating the endoglycosidase;
(e) desalting the de-glycosylated digested glycoprotein of step (d);
(f) analyzing the purified de-glycosylated digested glycoprotein by nano-flow LC-MS/MS, thereby generating reduced peptide mapping data; and
(g) determining post-translation modifications.

### Claim 2 (depends on 1)

The system of claim 1, further comprising validating the peptide mapping data by Extracted Ion Chromatograms (EICs) and MS spectra.

### Claim 3 (depends on 1)

The system of claim 1, further comprising identifying glycopeptides in the sample by setting GlcNAc and GlcNAc+Fuc as common variables occurring at Asn and Fc-glycosylation sites.

### Claim 4 (depends on 1)

The system of claim 1, further comprising identifying the non-consensus N-glycosylation and quantifying the glycosylation occupancy by data processing that can perform:
(i) screening of glycosylated Asn and glycosite locations,
(ii) analysis of peptide mapping data, and
(iii) determination of post-translation modifications.

### Claim 5 (depends on 4)

The system of claim 4, wherein the data processing is performed by a computer, cloud computing, and/or artificial intelligence (AI), and the endoglycosidase is Endo-F2.

### Claim 6 (depends on 1)

The system of claim 1, wherein the non-consensus N-glycosite is glycosylated with a glycan selected from the group consisting of G0F, G1F, G2F, G2FS, G2FS1, and G2FS2.

### Claim 7 (depends on 1)

The system of claim 1, wherein the non-consensus N-glycosite is located at a NPNNXN (SEQ ID NO: 1) sequence in a 25-residue long tryptic peptide, wherein X can be any amino acid.

### Claim 8 (depends on 1)

The system of claim 1, wherein the endoglycosidase-assisted peptide mapping workflow has a detectable glycosylation occupancy of about 0.2%.

### Claim 9 (depends on 1)

The system of claim 1, wherein the glycosylation occupancy is calculated as:
%
⁢
Occupancy
=
Peak
⁢
Area
(
PEP
+
GlcNAc
)
+
Peak
⁢
Area
(
PEP
+
GlcNAcFuc
)
Peak
⁢
Area
(
PEP
)
+
Peak
⁢
Area
(
PEP
+
GlcNAc
)
+
Peak
⁢
Area
(
PEP
+
GlcNAcFuc
)
*
1
⁢
00
⁢
%
.

### Claim 10 (depends on 1)

The system of claim 1, wherein the protein is selected from the group consisting of an antibody, antibody derivative, antibody fragment, a monoclonal antibody, a monospecific antibody, a bispecific antibody, an Fc-containing protein, and an Fc-fusion protein.

### Claim 11 (depends on 1)

The system of claim 1, wherein the de-glycosylated digested glycoprotein from step (c) is desalted by C18 pipette tips.

### Claim 12 (depends on 1)

The system of claim 1, wherein the post-translation modification is selected from the group consisting of oxidation, Asparagine (Asn) deamidation, and dehydration.

### Claim 13

A method of identifying non-consensus N-glycosylation and quantifying glycosylation occupancy in a protein, wherein the methods comprise the steps of
(a) providing a glycoprotein containing one or more non-consensus N-glycosites;
(b) digesting the glycoprotein using trypsin;
(c) de-glycosylating the digested glycoprotein by treatment with endoglycosidase;
(d) deactivating the endoglycosidase;
(e) desalting the de-glycosylated digested glycoprotein of step (c);
(f) analyzing the purified de-glycosylated digested glycoprotein by nano-flow LC-MS/MS, thereby generating reduced peptide mapping data; and
(g) determining post-translation modifications.

### Claim 14 (depends on 13)

The method of claim 13 further comprising validating the peptide mapping data by Extracted Ion Chromatograms (EICs) and MS spectra.

### Claim 15 (depends on 13)

The method of claim 13 further comprising identifying glycopeptides in the sample by setting GlcNAc and GlcNAc+Fuc as common variables occurring at Asn and Fc-glycosylation site.

### Claim 16 (depends on 13)

The method of claim 13 further comprising identifying the non-consensus N-glycosylation and quantifying the glycosylation occupancy by data processing that can perform:
(i) screening of glycosylated Asn and glycosite locations,
(ii) analysis of peptide mapping data, and
(iii) determination of post-translation modifications.

### Claim 17 (depends on 16)

The method of claim 16, wherein the data processing is performed by a computer, cloud computing, and/or artificial intelligence (AI), and the endoglycosidase is Endo-F2.

### Claim 18 (depends on 13)

The method of claim 13, wherein the non-consensus N-glycosite is glycosylated with a glycan selected from the group consisting of G0F, G1F, G2F, G2FS, G2FS1, and G2FS2.

### Claim 19 (depends on 13)

The method of claim 13, wherein the non-consensus N-glycosite is located at a NPNNXN (SEQ ID NO: 1) sequence in a 25-residue long tryptic peptide, wherein X can be any amino acid.

### Claim 20 (depends on 13)

The method of claim 13, wherein the endoglycosidase-assisted peptide mapping workflow has a detectable glycosylation occupancy of about 0.2%.

### Claim 21 (depends on 13)

The method of claim 13, wherein the glycosylation occupancy is calculated as:
%
⁢
Occupancy
=
Peak
⁢
Area
(
PEP
+
GlcNAc
)
+
Peak
⁢
Area
(
PEP
+
GlcNAcFuc
)
Peak
⁢
Area
(
PEP
)
+
Peak
⁢
Area
(
PEP
+
GlcNAc
)
+
Peak
⁢
Area
(
PEP
+
GlcNAcFuc
)
*
1
⁢
00
⁢
%
.

### Claim 22 (depends on 13)

The method of claim 13, wherein the protein is selected from the group consisting of an antibody, antibody derivative, antibody fragment, a monoclonal antibody, a monospecific antibody, a bispecific antibody, an Fc-containing protein, and an Fc-fusion protein.

### Claim 23 (depends on 13)

The method of claim 13, wherein the de-glycosylated digested glycoprotein from step (c) is desalted by C18 pipette tips.

### Claim 24 (depends on 13)

The method of claim 13, wherein the post-translation modification is selected from the group consisting of oxidation, Asparagine (Asn) deamidation, and dehydration.

### Claim 25 (depends on 13)

The method of claim 13, wherein the Endo-F2 enzyme is deactivated by acidifying with TFA.

### Claim 26

A method of identifying non-consensus N-glycosylation and quantifying glycosylation occupancy in a protein, wherein the methods comprise the steps of
(a) de-glycosylating a digested glycoprotein by treatment with endoglycosidase;
(b) deactivating the endoglycosidase;
(c) desalting the de-glycosylated digested glycoprotein of step (b);
(d) analyzing the desalted de-glycosylated digested glycoprotein by nano-flow LC-MS/MS, and thereby generating reduced peptide mapping data; and
(e) determining post-translation modifications.

### Claim 27 (depends on 26)

The method of claim 26, further comprising validating the peptide mapping data by Extracted Ion Chromatograms (EICs) and MS spectra.

### Claim 28 (depends on 26)

The method of claim 26, further comprising identifying glycopeptides in the sample by setting GlcNAc and GlcNAc+Fuc as common variables occur at Asn and Fc-glycosylation site.

### Claim 29 (depends on 26)

The method of claim 26, further comprising identifying the non-consensus N-glycosylation and quantifying the glycosylation occupancy by data processing that can perform:
(i) rapid screening of glycosylated Asn and glycosite locations,
(ii) the analysis of peptide mapping data, and
(iii) determining the post-translation modifications.

### Claim 30 (depends on 26)

The method of claim 26, wherein the data processing is performed by a computer, cloud computing and/or artificial intelligence (AI), and the endoglycosidase is Endo-F2.
